

## **AusCann appoints Chief Medical Advisor to accelerate medical engagement program**

**12 March 2020** – Medicinal cannabis pharmaceutical company **AusCann Group Holdings Limited** (ASX: AC8) ('AusCann' or 'the Company') is pleased to announce the appointment of Dr Marc Russo as AusCann's Chief Medical Advisor. Dr Russo replaces AusCann's previous chief medical advisor Dr Schecter. Dr Russo will lead AusCann's medical strategy which includes medical education, clinical evidence generation and clinical insights as the Company develops new product pipelines and intellectual property.

Dr Russo is a well-regarded specialist in pain medicine. He has treated over 20,000 patients since establishing Hunter Pain Clinic in 1999 (Australia's first multidisciplinary private pain clinic). Dr Russo is Deputy Chair of the NSW Regional Committee of the Faculty of Pain Medicine and of the Australian and New Zealand College of Anaesthetists (ANZCA). He has published over 40 scientific papers in his field and conducted 64 clinical trials. Dr Russo also brings experience in treating patients with cannabinoid-based medicines and related clinical trials.

AusCann has been advancing its Medical Outreach Program which provides doctors and health care practitioners access to cannabinoid medical resources. Under Dr Russo's leadership, AusCann will extend its Medical Outreach Program to include peer to peer education, guidance for clinical evaluation and the sharing of clinical best practice.

**AusCann CEO, Mr Ido Kanyon** commented: "We welcome Dr Marc Russo to the AusCann team. His extensive expertise in pain medicine along with his vision for cannabinoid-based medicines will be extremely valuable as we carry on our medical engagement program. The goal must be to provide clinical evidence and evidence-based information regarding cannabinoid medicines. Developing standardised products, generating clinical evidence and building medical acceptance will drive AusCann's value growth and result in better care for patients."

**ENDS**

This ASX announcement was authorised for release by the Board of AusCann.

### **For more information, please contact:**

#### **For Investment Enquiries**

Quentin Megson  
Chief Financial Officer  
info@auscann.com.au  
+61 8 9561 8834

#### **For Media Enquiries**

Elodie Castagna  
FTI Consulting  
elodie.castagna@fticonsulting.com  
+61 8 9321 8533

### **ABOUT AUSCANN**

**AusCann Group Holdings Limited** (ASX:AC8) is an Australian-based pharmaceutical company focused on the development, production, and distribution of cannabinoid-based medicines within Australia and internationally. AusCann transforms the way Medicinal Cannabis is dispensed today by making standardised dose-controlled cannabinoid-based pharmaceutical products and clinical evidence accessible to patients, physicians and healthcare providers. AusCann enables physicians to treat their patients with a reliable, stable and standardised cannabinoid-based pharmaceutical product, monitor treatment results and adjust treatment algorithms using a portfolio of products and formulations.